TNFSF13B and systemic lupus erythematosus: The anti-BAFF monoclonal antibody belimumab in two phase 3 trials in SLE demonstrated improvements in clinical measurements and biomarkers of disease activity [22, 23], and is approved for the treatment of SLE in the United States.